Hepatocellular Carcinoma in Renal Transplant Patients

Ridruejo, Ezequiel; Mandó, Oscar G.; Dávalos, M; Díaz, Carlos; Vilches, Antonio

doi:10.1016/j.transproceed.2005.03.010

Cited by 13 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study with small patient number, Cheng et al [2] reported that HCC patients, who could undergo resection, had a better outcome than those who received non-operative treatments. In contrast, Ridruejo et al [4] reported that prognosis is extremely poor if the HCCs are not resected.…”

Section: Discussionmentioning

confidence: 96%

“…In Taiwan, an endemic area of hepatitis B, hepatocellular carcinoma (HCC) has always ranked first in malignancy-related death [8]. The incidence of HCC in renal transplantation recipients in this endemic area is also high [2][3][4]. Although liver resection remains the main option for treating HCC with acceptable morbidity and mortality [9][10][11][12][13][14][15][16][17][18][19], only few authors have reported sporadic cases of liver resection for HCC after renal transplantation [2].…”

Section: Introductionmentioning

confidence: 99%

“…It should be performed in high-volume centers [9,10]. Moreover, similar to liver transplantation for HCC [20], continuous use of immunosuppressive drugs is associated with a high recurrent rate of HCC or other malignancies that may be expected after liver resection in renal transplantation recipients [2][3][4]6,7]. Thus, the role of surgical resection for HCC in this particular group of patients remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Liver resection for hepatocellular carcinoma in patients who have undergone prior renal transplantation

Cheng

Yeh

Shu

et al. 2006

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liver resection for hepatocellular carcinoma in patients who have undergone prior renal transplantation

Cheng

Yeh

Shu

et al. 2006

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…HCV‐induced cirrhosis is associated with a high risk of HCC development. HCC incidence may be higher in kidney transplant patients as compared to the general population . In countries with high prevalence rates for chronic hepatitis B and C, such as Taiwan, HCC can be the most common posttransplant malignancy .…”

Section: Natural History and Clinical Course Of Chronic Hepatitis Cmentioning

confidence: 99%

Hepatitis C Virus Infection and Kidney Transplantation in 2014: What’s New?

Baid-Agrawal

Pascual

Moradpour³

et al. 2014

American Journal of Transplantation

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection remains an important health problem, which is associated with deleterious consequences in kidney transplant recipients. Besides hepatic complications, several extrahepatic complications contribute to reduced patient and allograft survival in HCV‐infected kidney recipients. However, HCV infection should not be considered as a contraindication for kidney transplantation because patient survival is better with transplantation than on dialysis. Treatment of HCV infection is currently interferon‐alpha (IFN‐α) based, which has been associated with higher renal allograft rejection rates. Therefore, antiviral treatment before transplantation is preferable. As in the nontransplant setting, IFN‐free treatment regimens, because of their greater efficacy and reduced toxicity, currently represent promising and attractive therapeutic options after kidney transplantation as well. However, clinical trials will be required to closely evaluate these regimens in kidney recipients. There is also a need for prospective controlled studies to determine the optimal immunosuppressive regimens after transplantation in HCV‐infected recipients. Combined kidney and liver transplantation is required in patients with advanced liver cirrhosis. However, in patients with cleared HCV infection and early cirrhosis without portal hypertension, kidney transplantation alone may be considered. There is some agreement about the use of HCV‐positive donors in HCV‐infected recipients, although data regarding posttransplant survival rates are controversial.

show abstract

“…Salvage therapy with TDF or ADV is safe and effective in patients developing LAM-R. Despite this clear benefit, all HBV infected patients must be closely follow up and HCC screening must be performed every six months, since the risk of HCC development may not entirely disappears even in the presence of virological response [60,63] .…”

Section: Treatment Impact On Long Term Evolutionmentioning

confidence: 99%

Antiviral treatment for chronic hepatitis B in renal transplant patients

Ridruejo

2014

WJH

View full text Add to dashboard Cite

Chronic hepatitis B infection is frequent in renal transplant patients. It negatively impacts long term outcomes reducing graft and patient survival. Current guidelines clearly define who needs treatment, when to start, what is the first line therapy, how to monitor treatment response, when to stop, and how patients must be controlled for its safety. There is some data showing a favorable safety and efficacy profile of nucleos(t)ide analogue (NUC) treatment in the renal transplant setting. Entecavir, a drug without major signs of nephrotoxicity, appears to be the first option for NUC naïve patients and tenofovir remains the preferred choice for patients with previous resistance to lamivudine or any other NUC. Renal transplant recipients under antiHBV therapy should be monitored for its efficacy against HBV but also for its safety with a close renal monitoring. Studies including a large number of patients with long term treatment and follow up are still needed to better demonstrate the safety and efficacy of newer NUCs in this population. Core tip: Nucleos(t)ide analogue treatment is safe and effective in renal transplant patients. It improves long term patients and graft survival.Ridruejo E. Antiviral treatment for chronic hepatitis B in renal transplant patients.

show abstract

Hepatocellular Carcinoma in Renal Transplant Patients

Cited by 13 publications

References 17 publications

Liver resection for hepatocellular carcinoma in patients who have undergone prior renal transplantation

Liver resection for hepatocellular carcinoma in patients who have undergone prior renal transplantation

Hepatitis C Virus Infection and Kidney Transplantation in 2014: What’s New?

Antiviral treatment for chronic hepatitis B in renal transplant patients

Contact Info

Product

Resources

About